News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

GBI Research Release: Contract Manufacturing in India and China Backed by Government Policies



5/16/2012 9:23:32 AM

NEW YORK (GBI Research), 16 May 2012 - Contract Manufacturing Organizations (CMO) will reap the rewards as pharmaceutical production becomes increasingly globalized, according to a new report by business intelligence experts GBI Research.

The new report* anticipates that the global CMO market will grow steadily due to the increased outsourcing of pharmaceutical production by Western pharmaceutical manufacturers to Asian countries. The availability of adequate numbers of current good manufacturing practices and compliant manufacturing sites in Asia make India and China popular outsourcing destinations of choice for CMOs.

India and China represent the fastest-growing countries in the CMO services sector having witnessed drastic changes in their government and regulatory policies that encourage pharmaceutical outsourcing in order to increase business and attract foreign clients. For example, in 2005, the Indian Biotechnology Policy issued simplified procedures for regulatory clearance and exemptions from import duties and service taxes, encouraging foreign investments within the country. In China, the State Food and Drug Administration (SFDA) has clearly stated contract manufacturing as a long-term goal for the country’s economic growth. In early 2001, Article 13 of the new edition of the “Drug Administration Law” was issued, legalizing pharmaceutical contract manufacturing in China. In August 2003, the SFDA clarified, in the trial version of the “Regulations on Processing Drug for Export”, that Chinese drug manufacturers may conduct contract manufacturing for a pharmaceutical company outside China.

Furthermore, the introduction of the new patent regime in India during January 2005 encouraged multinational pharmaceutical companies looking to outsource their manufacturing of branded drugs with the protection of Intellectual Property Rights (IPRs). The amendment of the Schedule Y article allows parallel phase clinical trials to be conducted along with reductions in custom duties for clinical trial samples being imported. However, GBI Research analysis suggests that many Eastern Europe countries may offer superior IPR protection compared to their Asian counterparts, which lack an effective enforcement framework and witness more instances of IPR violation.

The global CMO market was valued at $26 billion in 2010. Driven by increases in the sourcing of biologics and generic manufacturing, the market is forecast to reach approximate revenues of $59.9 billion by 2018.

*Contract Manufacturing Organizations to 2018 - Cost Advantages and Improving Quality Standards Build Confidence and Encourage Foreign Investment in Asian CMOs

This report provides key data, information and analysis of Contract Manufacturing Organization (CMO) industry. It gives a comprehensive insight into the size of the CMO market, and includes forecasts, key reasons for outsourcing, market characterization of CMO’s, profiles of top CMOs, regulatory frameworks, drivers and restraints and deals analysis. This report is built using data and information sourced from proprietary databases, primary and secondary research and uses in-house analysis from GBI Research’s team of industry experts.

-ABOUT GBI RESEARCH-

GBI Research is a market-leading provider of business intelligence reports, offering actionable data and forecasts based on the insights of key industry leaders to ensure you stay up-to-date with the latest emerging trends in your markets.

For more information, please contact our Press Office on +44 (0)1204 543 537 or at pr@gbiresearch.com.


Read at BioSpace.com


comments powered by Disqus
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES